目的 探討鎮(zhèn)腦寧聯(lián)合阿魏酸鈉治療偏頭痛的有效性與安全性。方法 選取鄭州人民醫(yī)院2016年4月—2017年4月收治的偏頭痛患者114例，按照就診順序分成對照組和治療組，每組各57例。對照組患者口服阿魏酸鈉片，2片/次，3次/d；治療組患者在對照組治療基礎上口服鎮(zhèn)腦寧膠囊，4粒/次，3次/d。兩組患者治療6個月。觀察兩組患者臨床療效，同時比較治療前后兩組患者頭痛發(fā)作次數(shù)、持續(xù)時間和VAS評分及血清超敏C反應蛋白（hs-CRP）、同型半胱氨酸（Hcy）和基質(zhì)金屬蛋白酶9（MMP-9）水平。結(jié)果 治療后，對照組和治療組臨床有效率分別為84.21%和96.49%，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組患者的頭痛發(fā)作次數(shù)、持續(xù)時間和頭痛VAS評分較治療前均顯著降低（P<0.05），且治療組患者頭痛發(fā)作次數(shù)、持續(xù)時間和VAS評分明顯低于對照組（P<0.05）。治療后，兩組患者血清hs-CRP、Hcy和MMP-9水平顯著降低（P<0.05），且治療組患者血清hs-CRP、Hcy和MMP-9水平明顯低于對照組（P<0.05）。結(jié)論 鎮(zhèn)腦寧聯(lián)合阿魏酸鈉治療偏頭痛臨床效果顯著、安全性好，具有一定的臨床推廣應用價值。

Objective To investigate the clinical efficacy and safety of Zhennaoning Capsules combined with sodium ferulate in treatment of migraine. Methods Patients (114 cases) with migraine in People's Hospital of Zhengzhou from April 2016 to April 2017 were divided into control and treatment groups according to the order of the treatment, and each had 57 cases. Patients in the control group were po administered with Sodium Ferulate Tablets, 2 tablets/time, three times daily. Patients in the treatment group were po administered with Zhennaoning Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 6 months. After treatment, the clinical efficacy was evaluated, and the frequency and duration of headache, and VAS scores, the serum hs-CRP, Hcy and VEGF levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 84.21% and 96.49% respectively, and there were differences between two groups (P<0.05). After treatment, the frequency and duration of headache, and VAS scores in two groups were significantly decreased (P<0.05), which in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the hs- CRP, Hcy and MMP-9 levels in two groups were significantly decreased (P<0.05), and these indexes in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Zhennaoning Capsules combined with sodium ferulate in treatment of migraine has significant clinical effect and high safety, which has a certain clinical application value.